2025-10-09 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM) based on the data you provided. The report is structured to include numerical summaries, followed by brief analytical comments for each section.

## Tempus AI (TEM) Stock Analysis

**Company Overview:** Tempus AI is a company focusing on precision medicine through data analysis and AI applications.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 65.40%
*   **VOO Cumulative Return:** 28.84%
*   **Absolute Divergence:** 19.1
*   **Relative Divergence:** 51.9 (Positioned at the 51.9th percentile within its historical divergence range).

**Analysis:** TEM has significantly outperformed the S&P 500 over the analyzed period. The relative divergence suggests that while currently positive, there is still room for fluctuation within its historical range.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 65.0% | 70.1% | 38.0% | 0.3 | 17.9 |

*   **CAGR (2023-2025):** 65.0%
*   **MDD (2023-2025):** 70.1%
*   **Alpha (2023-2025):** 38.0%
*   **Beta (2023-2025):** 0.3
*   **Cap(B) :** 17.9B

**Analysis:** The high CAGR indicates strong growth, but also consider the high MDD, representing high volatility. The alpha of 38.0% suggests significant outperformance relative to the market, while the low beta of 0.3 indicates lower sensitivity to market movements.

### 2. Recent Price Action

*   **Current Price:** 103.25
*   **Last Market Change:** Price: 103.25, Previous Close: 93.01, Change: 11.01
*   **5-Day Moving Average:** 94.06
*   **20-Day Moving Average:** 86.47
*   **60-Day Moving Average:** 74.22

**Analysis:** The current price is well above all moving averages, suggesting a strong uptrend. The significant "change" from the previous close (11.01) reflects a sharp increase in price, possibly due to recent news or events.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment Recommended)
*   **RSI:** 71.21 (Approaching overbought territory)
*   **PPO:** 1.46
*   **Hybrid Signal:** Buy 100% (11 shares - Very Safe - MRI:0.90)
*   **20-Day Relative Divergence Change:** 14.9 (+) (Short-term Increase)
*   **Expected Return (%):** NaN

**Analysis:** The MRI suggests that TEM is currently considered to be in the medium-risk investment category. An RSI above 70 typically indicates overbought conditions. The positive change in relative divergence indicates a recent increase in performance compared to the benchmark. The Hybrid signal gives a "Buy" recommendation. A large price change (11.01) reflects a market reaction, potentially to news.

### 4. Recent News & Significant Events

*   **Oct 08, 2025:** Bull Case Theory (Insider Monkey)
*   **Oct 05, 2025:** FDA Clearance for xR IVD Device (Insider Monkey)
*   **Oct 01, 2025:** Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution (Business Wire)
*   **Sep 29, 2025:** Assessing Valuation as Investor Interest Grows (Simply Wall St.)
*   **Sep 26, 2025:** TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? (Zacks)
*   **Sep 22, 2025:** Pulls Back From Record High After Another FDA Clearance (Investor's Business Daily)

**Analysis:** The recent news is largely positive, highlighting FDA clearance and a bull case theory, which likely contributed to the recent price surge. However, there are also articles questioning the valuation.

#### 4.2 Analyst Opinions

*   **Consensus:** Buy (Mean: 2.15)
*   **Opinions:** 11
*   **Target Price:** Avg: 77.55 / High: 100.00 / Low: 60.00
*   **Recent Rating Changes:** No significant rating changes reported.

**Analysis:** Analyst consensus is generally positive ("Buy"), though the average target price is below the current market price, suggesting potential overvaluation.

### 5. Recent Earnings Analysis

| 날짜         | EPS    | 예상 EPS |
|--------------|--------|----------|
| 2025-08-08   | -0.22  | -0.22988 |
| 2025-05-06   | -0.24  | -0.26003 |
| 2025-02-24   | -0.18  | -0.15    |
| 2024-11-04   | -0.25  | -0.26608 |
| 2024-08-06   | -0.63  | -0.59    |

**Analysis:** TEM has consistently reported negative EPS, although it has often exceeded (reported a smaller loss than) analyst expectations.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.31B  | -13.84%   |
| 2025-03-31 | $0.33B  | -20.86%   |
| 2024-12-31 | $0.06B  | -23.10%   |
| 2024-09-30 | $0.05B  | -141.16%  |
| 2024-06-30 | $0.10B  | -562.04%  |

**Analysis:** Revenue is increasing steadily, and profit margins are relatively high and stable. However, the company has negative ROE, indicating that it is not generating profits from its equity.

### 7. Overall Summary

Tempus AI (TEM) has demonstrated significant outperformance compared to the S&P 500, driven by positive news and investor sentiment. Recent price action is very bullish, with the stock trading well above its moving averages. Technical indicators suggest overbought conditions. Analyst consensus is "Buy," but the average target price is below the current market price. The company is growing revenue with high profit margins.
However, the high MDD and negative ROE and EPS results need to be noted, with high caution. Also the analyst opinions show there could be an overevaluation with the current price.
